Rock Creek Group’s Quest Diagnostics DGX Stock Holding History

Rock Creek Group’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-120	Closed	-$15K	–	206
2021 Q1	$15K	Buy	+120	New	+$14.8K	﹤0.01%	181

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Rock Creek Group's DGX Position: Q2 2021 in Review

Rock Creek Group sold out of Quest Diagnostics (DGX) in Q2 2021, closing a stake of 120 shares — an estimated $15K sold.

Rock Creek Group first reported a position in DGX in Q1 2021 and held it in 1 quarter. The position peaked at $15K in Q1 2021. 814 funds tracked by Wall St. Rank hold DGX as of Q2 2021.

Rock Creek Group reported no remaining Quest Diagnostics position as of Q2 2021 after selling out during the quarter.
Rock Creek Group sold 120 Quest Diagnostics shares in Q2 2021, an estimated $15K.
Rock Creek Group first reported a position in Quest Diagnostics in Q1 2021 and held it in 1 quarter.
Rock Creek Group's Quest Diagnostics position peaked at $15K in Q1 2021.
814 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2021.

Based on Rock Creek Group's 13F filing for Q2 2021, filed 10 Aug 2021.